Research programme: virus vaccines - Crucell/National Institutes of Health
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Crucell; National Institutes of Health (USA)
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ebola virus infections; Lassa fever; Marburg virus disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA (Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lassa-fever in USA (Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Marburg virus disease in USA (Injection)